The licences will allow manufacturers from around the world to work with MPP and C-TAP to make these technologies accessible to people living in low- and middle-income countries
CB03 is a candidate drug for the treatment of refractory epilepsy, independently developed by Zhimeng
Deucravacitinib is currently under regulatory review in multiple regions, including the U.S., Europe and Japan, and would be the first selective allosteric tyrosine kinase 2 (TYK2) inhibitor approved for the treatment of any disease
“We are committed to making India a global medical value hub by further strengthening our traditional medicine industry and boosting 'Heal in India' & 'Heal by India'
The new logo is a refreshing change from the version that has served Hetero well for three decades. And yet its reflection can be seen in the new version
Company's net income rose by 57.5 percent to 3.291 billion euros in Q1
Myovant to receive an upfront payment of US $50 million, is eligible to receive commercial launch, sales-based and other milestones totaling up to US $90.5 million
To lay a technological foundation for developing exosome-based medicines and cosmetic products for dermatitis treatment
If granted, Nuvaxovid would be the first protein-based Covid-19 vaccine option for adolescents in Australia and New Zealand
The department will soon release a policy to catalyze research & development and innovation in the pharma- Medtech sector in India
Subscribe To Our Newsletter & Stay Updated
